Medicare AdvantagePrior AuthMedium impact
Mektovi (binimetinib) (Revised)
Humana·Oncology·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has updated prior authorization requirements for Mektovi (binimetinb) effective January 1, 2026. The policy requires specific BRAF mutation documentation and combination therapy with Braftovi for both unresectable/metastatic melanoma and metastatic non-small cell lung cancer.
Action Required
By January 1, 2026: Billing team must ensure prior authorization is obtained for all Mektovi (binimetinib) prescriptions for Medicare Advantage patients. Verify patients have documented BRAF V600 mutations (V600E or V600K for melanoma, V600E for NSCLC) and will use Mektovi in combination with Braftovi. Update prior auth checklists to exclude patients on concomitant immunotherapy drugs or those who have progressed on prior anti-BRAF/MEK therapy.